Idiopathic Inflammatory Myopathies: Current Trends in Pathogenesis, Clinical Features, and Up-to-Date Treatment Recommendations

Division of Rheumatology, Mayo Clinic, Rochester, MN. Electronic address: .
Mayo Clinic Proceedings (Impact Factor: 6.26). 01/2013; 88(1):83-105. DOI: 10.1016/j.mayocp.2012.10.017
Source: PubMed


Recently, there have been important advances in the understanding of the pathophysiologic features, assessment, and management of patients with a newly diagnosed idiopathic inflammatory myopathy (IIM). Myositis-specific autoantibodies have been identified to define patient subgroups and offer prognostic implications. Similarly, proinflammatory cytokines, such as interleukin 6 and type 1 interferon-dependent genes, may serve as potential biomarkers of disease activity in adult and juvenile patients with dermatomyositis (DM). Moreover, magnetic resonance imaging has become an important modality for the assessment of muscle inflammation in adult IIM and juvenile DM. Immune-mediated necrotizing myopathies also are being recognized as a subset of IIM triggered by medications such as statins. However, confusion exists regarding effective management strategies for patients with IIM because of the lack of large-scale, randomized, controlled studies. This review focuses primarily on our current management and treatment algorithms for IIM including the care of pediatric patients with juvenile DM. For this review, we conducted a search of PubMed and MEDLINE for articles published from January 1, 1970, to December 1, 2011, using the following search terms: idiopathic inflammatory myopathies, dermatomyositis, polymyositis, juvenile dermatomyositis, sporadic inclusion body myositis, inclusion body myositis, inflammatory myositis, myositis, myopathies, pathogenesis, therapy, and treatment. Studies published in English were selected for inclusion in our review as well as additional articles identified from bibliographies.

Full-text preview

Available from:
  • Source
    • "Notably, BXL-01-0029 similarly to elocalcitol, another nonhypercalcemic VDR agonist, does not affect cell viability in several types of organ resident cells and in CD4+ T cells, while significantly decreasing Th1- and Th17-cytokine secretion [20, 101]. Conversely, the majority of immunosuppressants have been designed to reduce the number of immune cells; this specific effect accomplishes the appearance of the well known noxious side effects of immunosuppressive drugs, that is, from metabolic disturbances, to opportunistic infections or tumor development [13–15]. So far, VDR agonists are likely able to control immune reaction acting essentially onto the production of mediators of inflammation, cytokines, and chemokines. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The primary aim in the treatment of autoimmune inflammatory myopathies (IMs) is to recover muscle function. The presence of immune/inflammatory cell infiltrates within muscle tissues represents the common feature of different IM subtypes, albeit a correlation between muscular damage extent and inflammation degree is often lacking. Treatments for IMs are based on life-long immunosuppressive therapy, with the well known adverse effects; recovery is incomplete for many patients. More effective therapies, with reduced side-effects, are highly desirable. Vitamin D receptor (VDR) agonists emerge to retain pleiotropic anti-inflammatory properties, since they regulate innate and adaptive immunity by switching the immune response from proinflammatory T helper 1 (Th1) type to tolerogenic T helper 2 (Th2) type dominance. In skeletal muscle cells less hypercalcemic VDR ligands target powerful mediators of inflammation, such as TNF α and TNF α driven paths, without affecting immune or muscle cells viability, retaining the potentiality to counteract Th1 driven overreactivity established by the self-enhancing inflammatory loop between immune and skeletal muscle cells. This review summarizes those features of VDR agonists as candidates in future treatment of IM.
    Full-text · Article · May 2014 · BioMed Research International
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To assess the efficacy and safety of rituximab (RTX) on disease activity and muscle strength in patients with inflammatory myopathies refractory to conventional therapy.
    Preview · Article · Jan 2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the diagnosis of inflammatory myopathies the initial symptom is muscle weakness. Exclusion of another causes of myopathies such as metabolic, toxic neuropathies etc. is very important. The confirmation of that weakness in the physical examination, and other additional data: the elevation of muscle enzymes in blood, determination roughly antibody tests, imaging tests, and histological examination of the muscle biopsy obtained lead to the end diagnosis. The muscle involvement is patchy, sometimes performing nuclear magnetic resonance is needed for to choose where do the muscle biopsy to optimizes the histologycal result. If dermatomyositis diagnosis was made, because the association between this and neoplastic processes, we must be continue investigate the possibility of the existence of concomitant tumor.
    No preview · Article · Mar 2013 · Medicine - Programa de Formación Médica Continuada Acreditado
Show more